Tools for Practice Outils pour la pratique

#285 Should a ‘flozin be chosen to play a part for a failing heart?

What is the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with chronic heart failure with reduced ejection fraction?

SGLT2i reduce mortality, heart failure hospitalizations, and improve quality of life when added to other medications in patients with heart failure with reduced ejection fraction, with or without diabetes. For every 100 patients treated with an SGLT2i for ~1.5 years, ~2 fewer will die, ~4 fewer will be hospitalized for heart failure, and ~7 will have improved quality of life (by 8 months) compared to placebo.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

Two industry-funded, randomized, placebo-controlled trials1,2 of patients with heart failure and ejection fraction ≤40% (mainly NYHA class 2-3, 47% with diabetes, average systolic blood pressure 122 mm Hg, 65% on combination betablocker/renin-angiotensin system blocker/mineralocorticoid receptor antagonist3). Results statistically different unless indicated.
  • DAPA-HF:1 4744 patients, dapagliflozin 10mg daily.
    • At 18 months:
      • Mortality: 11.6% versus 13.9% (placebo), number needed to treat (NNT)=44.
      • Heart failure hospitalization: 9.7% versus 13.4% (placebo), NNT=27.
    • At 8 months:
      • 58.3% versus 50.9% (placebo) achieved minimal important improvement in quality of life (≥5 points on 100-point scale), NNT=14.
    • Adverse events: No difference.
  • EMPEROR-Reduced:2 3730 patients, empagliflozin 10mg daily. At 16 months:
    • Mortality: 13.4% versus 14.2% (placebo), not statistically different.
    • Heart failure hospitalization: 13.2% versus 18.3% (placebo), NNT=20.
    • Adverse events:
      • Genital infections: 1.7% versus 0.6% (placebo), NNH=91.
  • One meta-analysis4 including both trials:
    • Reduction in mortality (NNT=61) and heart failure hospitalization (NNT=24).
    • Similar efficacy in those with or without diabetes, and with or without sacubitril-valsartan.
  • SGLT2i efficacy comparable to other heart failure medications:5,6
    • Mortality: Relative risk reduction ~13% (others ~16-35%).
    • Heart failure hospitalization: Relative risk reduction ~30% (others ~20-35%).
  • Unlike other heart failure medications, SGLT2i do not seem to cause significant hypotension or electrolyte abnormalities.1,2,4
  • Canadian guidelines7 recommend SGLT2i for patients with “mild to moderate” heart failure, though sequence not specified (e.g. whether to consider SGLT2i prior to sacubitril-valsartan).
  • Splitting empagliflozin 25mg in half=12.5 mg (trial dose=10 mg) cuts cost in half (to ~$560/year).8

Yan Kai Yung April 5, 2021

loosing glucose in urine helps to control DM and overweight in Diabetic patients, but for non Diabetic patients with low BMI, can SGLT2i cause issue of malnutrition ?

James Lanz-O'Brien April 24, 2021

I was an early adopter of SGLT2 inhibitors for this indication into my practice. One other benefit that is important to consider is that they do not disturb serum sodium or potassium.

Dominic Tsang May 1, 2021

good tip in saving money with halting the pill

Gilbert Bretecher May 3, 2021

I have started using Flozins for CHF patients in my practice

Latest Tools for Practice
Derniers outils pour la pratique

#369 Remind me, do medications that target brain amyloid improve my dementia?

Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment or Alzheimer’s dementia?
Read Lire 0.25 credits available Crédits disponibles

#368 Sodium Restriction in Heart Failure: Beneficial or pouring salt in the wound?

Does sodium restriction improve outcomes in patients with chronic heart failure?
Read Lire 0.25 credits available Crédits disponibles

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Jamie Falk BSc(Pharm) PharmD
  • Jennifer Potter MD CCFP
  • Ricky D. Turgeon BSc(Pharm) ACPR PharmD

1. McMurray JJV, Solomon SD, Inzucchi SE, et al. N Eng J Med 2019; 381:1995-2008.

2. Packer M, Anker SD, Butler J, et al. N Eng J Med 2020; Aug 29. doi: 10.1056/NEJMoa2022190.

3. Docherty KF, Jhund PS, Inzucchi SE, et al. Eur Heart J 2020; 41:2379-92.

4. Zannad F, Ferreira JP, Pocock SJ, et al. Lancet. 2020 Sep 19; 396(10254):819-829.

5. Lindblad AJ, Allan GM. Can Fam Physician 2014 Feb; 60:e104.

6. Sehn E, McDonald T, Lindblad AJ. Can Fam Physician 2017 Sep; 63(9):697.

7. O'Meara E, McDonald M, Chan M, et al. Can J Cardiol 2020; 36:159e169.

8. Alberta College of Family Physicians Price Comparison of Commonly Prescribed Pharmaceuticals in Alberta 2019. Accessed 8 Dec, 2020.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.